Ventyx Biosciences (NASDAQ:VTYX – Get Rating) announced its quarterly earnings data on Thursday. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.07, MarketWatch Earnings reports.
Shares of VTYX opened at $14.91 on Friday. Ventyx Biosciences has a 12 month low of $9.50 and a 12 month high of $26.00. The stock has a fifty day moving average price of $13.44 and a 200-day moving average price of $15.42.
A number of hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its stake in Ventyx Biosciences by 3.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 73,803 shares of the company’s stock worth $1,002,000 after acquiring an additional 2,482 shares during the last quarter. Citigroup Inc. purchased a new position in Ventyx Biosciences in the 4th quarter worth $56,000. California State Teachers Retirement System purchased a new position in Ventyx Biosciences in the 4th quarter worth $114,000. Wells Fargo & Company MN purchased a new position in Ventyx Biosciences in the 4th quarter worth $121,000. Finally, Deutsche Bank AG acquired a new stake in Ventyx Biosciences during the 4th quarter worth about $126,000. Institutional investors own 62.30% of the company’s stock.
About Ventyx Biosciences (Get Rating)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus.
- Get a free copy of the StockNews.com research report on Ventyx Biosciences (VTYX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Want More Great Investing Ideas?
- 3 Stocks to DOUBLE This Year
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 9 "MUST OWN" Growth Stocks
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.